Trial Profile
An Open Label, Non-randomised, Parallel Group Study to Characterise and Compare the Pharmacokinetics, Safety and Tolerability of a Single Dose of AGO178C in Subjects With Mild, Moderate, Severe Renal Impairment and End-stage Renal Disease With That in Healthy Matched Control Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Dec 2020
Price :
$35
*
At a glance
- Drugs Agomelatine (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 27 Oct 2011 New trial record